MDAI Share Price Performance
US$1.56
0.11 (7.59%)
69.4% undervalued intrinsic discount
US$5.09
Fair Value
Price US$1.56
AnalystConsensusTarget US$5.09
AnalystLowTarget US$3.50
AnalystHighTarget US$7.45
Fair ValueUS$5.09
Share Pricen/a
Spectral AI, Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
MDAI Community Narratives
AN
Fair Value US$5.09 69.4% undervalued intrinsic discount
FDA Approval And BARDA Contracts Will Boost Clinical Diagnostics
0users have liked this narrative
1users have commented on this narrative
10users have followed this narrative
AN
Fair Value US$3.5 55.4% undervalued intrinsic discount
Regulatory Pressures Will Stifle Growth Despite Nascent Market Improvements
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$7.45 79.1% undervalued intrinsic discount
DeepView Device Will Catalyze Personalized Remote Diagnostic Care
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
DeepView Device Will Catalyze Personalized Remote Diagnostic Care
Key Takeaways Strong government partnerships and early regulatory momentum uniquely position Spectral AI for rapid, high-margin commercial growth and sustained long-term contracts. Expansion into telemedicine, intellectual property monetization, and AI-powered personalized medicine cement Spectral AI's leadership and drive future revenue and margin gains.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$7.45
79.1% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
52.06% p.a.
Profit Margin
29.15%
Future PE
10.58x
Share price in 2028
US$5.09
Regulatory Pressures Will Stifle Growth Despite Nascent Market Improvements
Key Takeaways Rising regulatory scrutiny and evolving requirements could increase costs, slow adoption, and challenge profitability despite promising healthcare AI opportunities. Heavy dependence on government funding and industry consolidation may cause unpredictable revenue streams and persistent pressure on margins.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$3.5
55.4% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
-42.55% p.a.
Profit Margin
12.49%
Future PE
215.59x
Share price in 2028
US$2.39
FDA Approval And BARDA Contracts Will Boost Clinical Diagnostics
Key Takeaways Anticipated regulatory approval and expanded partnerships pave the way for recurring high-margin revenues and greater earnings stability. Advancements in the DeepView platform and operational efficiencies position the company to capitalize on rising demand for AI-driven diagnostics.Read more
0users have liked this narrative
1users have commented on this narrative
10users have followed this narrative
AN
US$5.09
69.4% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
17.89% p.a.
Profit Margin
12.34%
Future PE
32.63x
Share price in 2028
US$3.5
Recently Updated Narratives
AN
Regulatory Pressures Will Stifle Growth Despite Nascent Market Improvements
Fair Value: US$3.5 55.4% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
DeepView Device Will Catalyze Personalized Remote Diagnostic Care
Fair Value: US$7.45 79.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FDA Approval And BARDA Contracts Will Boost Clinical Diagnostics
Fair Value: US$5.09 69.4% undervalued intrinsic discount
10 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Spectral AI, Inc. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.53
- 45.01%
- -70.64%
- -95.0%
About MDAI
- Founded
- n/a
- Employees
- 78
- CEO
- WebsiteView website
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States. The company offers DeepView System, which uses proprietary AI algorithms to distinguish between fully damaged, partially damaged, and healthy human tissue characteristics invisible to the naked eye at the initial time point of wound presentation; and delivers a binary prediction on the wounds capacity to heal or not heal by a specified time point in the future to assist the physician in making a more accurate, timely, and informed decision regarding the treatment of the patient’s wounds. Its system also includes MSI imaging technology, which consists of proprietary multi-spectral optics and sensors that capture injured tissue images; and AI-Burn software. Spectral AI, Inc. is headquartered in Dallas, Texas.
